Furthermore, given that androgens are the main inducers of prostate tumor growth and that the function of these steroids depends on interaction with their receptor, the use of drugs that prevent, compete with or modify the conformation of the androgen receptor could be used as therapies to inhibit the expression of genes involved in androgen-dependent cancer cell proliferation. Here, AR is linked to prostate neoplasm.